KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $748.1 million.

  • Eli Lilly's Deferred Taxes fell 2260.5% to $748.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year decrease of 3637.72%. This contributed to the annual value of $1.7 billion for FY2025, which is 3637.72% down from last year.
  • As of Q4 2025, Eli Lilly's Deferred Taxes stood at $748.1 million, which was down 2260.5% from -$501.4 million recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Deferred Taxes ranged from a high of $1.1 billion in Q3 2022 and a low of -$501.4 million during Q3 2025
  • In the last 5 years, Eli Lilly's Deferred Taxes had a median value of $468.6 million in 2023 and averaged $485.9 million.
  • As far as peak fluctuations go, Eli Lilly's Deferred Taxes skyrocketed by 496730.77% in 2023, and later tumbled by 21665.89% in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's Deferred Taxes stood at $92.5 million in 2021, then crashed by 111.24% to -$10.4 million in 2022, then soared by 4967.31% to $506.2 million in 2023, then soared by 90.95% to $966.6 million in 2024, then fell by 22.61% to $748.1 million in 2025.
  • Its Deferred Taxes stands at $748.1 million for Q4 2025, versus -$501.4 million for Q3 2025 and $1.1 billion for Q2 2025.